GLP-1 Medications and Coronary Artery Calcium Screening: What Every Man Needs to Know About His Heart

Most men don’t think seriously about their heart until something goes wrong. But here’s a number worth sitting with: a 2025 analysis published in JACC Cardiovascular Imaging found that among overweight men and women without diabetes or established cardiovascular disease, than those with a CAC score of zero — to the point where the number needed to treat to prevent a major adverse cardiovascular event dropped significantly in higher-CAC groups. In other words, a simple, non-invasive scan could tell you whether a blockbuster weight-loss drug is likely to meaningfully protect your heart, or whether your cardiovascular risk is low enough that lifestyle alone may be sufficient. That’s a powerful piece of clinical intelligence — and most men have never heard of it.

This matters far beyond GLP-1 medications. Coronary artery calcium scoring is one of the most underutilized tools in preventive cardiology, and understanding what it measures — and what to do with that information — is relevant whether you’re on semaglutide, lifting four days a week, eating a clean whole-food diet, or some combination of all three. Your CAC score doesn’t care how you’re pursuing better health. It just tells you how much silent damage has already accumulated in your arteries.

What Coronary Artery Calcium Actually Measures — And Why It Changes Everything

Atherosclerosis, the gradual buildup of plaque inside coronary arteries, is largely a silent process. You can have meaningful arterial disease with no symptoms, no warning, and no obvious signal from standard blood work. Coronary artery calcium scoring uses a low-radiation CT scan — no contrast dye required — to detect and quantify calcified plaque in the coronary arteries. The result is expressed as a numerical score. A score of zero means no detectable calcified plaque. Scores above 100 or 400 indicate progressively higher atherosclerotic burden and risk.

The 2019 ACC/AHA Guidelines on Primary Prevention of Cardiovascular Disease explicitly endorse CAC scanning as a tool to guide shared decision-making about statin therapy in intermediate-risk patients — those for whom the standard 10-year ASCVD risk calculator leaves the clinical picture ambiguous. The guidelines position CAC as a tiebreaker: if you and your doctor are on the fence about whether to start a statin, a CAC score of zero may reasonably support deferring medication and doubling down on lifestyle, while a score above 100 tips the scales toward pharmacological intervention. This isn’t fringe medicine. It’s guideline-backed, it costs roughly $100-$200 out of pocket at most imaging centers, and it takes about 10 minutes.

The clinical value of this scan extends well beyond statin decisions. For men with metabolic risk factors — insulin resistance, elevated triglycerides, hypertension, abdominal obesity — CAC scoring provides a ground-truth snapshot of cardiovascular age that no blood panel can fully replicate. A 45-year-old man with a CAC score of 250 has arteries that are behaving like those of a much older man, regardless of what his LDL says. That information should change how aggressively he pursues every tool available: dietary change, exercise, sleep optimization, stress management, and where appropriate, medication.

Where GLP-1 Medications Fit Into This Picture

The intersection of GLP-1 receptor agonists and cardiovascular risk is one of the most compelling developments in metabolic medicine in the past decade. Semaglutide — the active compound in Ozempic and Wegovy — demonstrated in the SELECT trial that it reduced major adverse cardiovascular events by approximately 20% in overweight and obese individuals without diabetes who already had established cardiovascular disease. The 2025 MESA analysis took that finding and asked a different question: what about people who don’t yet have established CVD? Can we identify who among them would benefit most from semaglutide’s cardiovascular effects?

The answer, according to that JACC analysis of 3,129 MESA participants, is yes — and CAC score is a strong predictor of who that is. Among individuals with a CAC score of zero, the 5-year number needed to treat to prevent a MACE event was high, meaning relatively few people would benefit from the drug’s cardiovascular effects. Among those with CAC above 100 or 400, the number needed to treat dropped substantially — meaning far more people in those groups would derive meaningful cardiovascular protection from semaglutide, in addition to its weight-loss effects. This reframes how we think about allocating an expensive, supply-constrained medication. It also reinforces that semaglutide isn’t simply a weight-loss drug with cardiac side benefits — for high-CAC individuals, the cardiovascular protection may be one of its most important functions.

Tirzepatide, the dual GIP/GLP-1 agonist marketed as Mounjaro and Zepbound, is now the subject of the T-Plaque trial — a randomized controlled study designed to measure whether tirzepatide actually slows coronary plaque progression as assessed by CT angiography in adults with type 2 diabetes and documented coronary stenosis. Participants undergo baseline coronary calcium scoring alongside detailed plaque volume and composition analysis, then repeat imaging at one year. This is the first trial of its kind for tirzepatide, and its results will likely redefine how cardiologists and endocrinologists think about this class of drugs in atherosclerotic disease management. We don’t have the results yet, but the fact that the trial was designed around imaging plaque directly — not just measuring cardiovascular events statistically — represents a significant methodological leap.

For men with type 2 diabetes, the cardiovascular stakes are even higher. Diabetic cardiomyopathy is a well-documented but chronically underrecognized condition in which abnormal cardiac structure and function develop silently, independent of coronary artery disease, hypertension, or valvular disease. This asymptomatic stage — Stage B heart failure — can progress to overt, symptomatic heart failure without ever triggering obvious warning signs. GLP-1 receptor agonists have demonstrated reductions in major adverse cardiovascular events in trials of diabetic populations, though their direct effect on heart failure outcomes has been less consistent than SGLT-2 inhibitors. The practical implication for men with T2D is that managing blood sugar aggressively and early — with whatever combination of lifestyle and pharmacotherapy is appropriate — isn’t just about avoiding amputations and kidney disease. It’s about preserving a heart that may already be silently compromised.

It’s worth noting that the cardiovascular risk-enhancing effects of metabolic dysfunction extend across a range of conditions. Research on insulin-resistant populations — including those with hormonal and metabolic disorders — suggests that measurement of subclinical atherosclerosis via carotid plaque or coronary artery calcium may be a useful tool to guide shared decision-making about statin therapy when CVD risk is uncertain. when risk calculators alone leave the picture unclear. The same logic applies to any man with significant insulin resistance, metabolic syndrome, or a family history of premature coronary disease. CAC scoring doesn’t belong to any one diagnosis. It belongs to anyone trying to make informed decisions about their cardiovascular future.

What This Means For You

If you’re a man between 40 and 65 with any metabolic risk factors — abdominal obesity, elevated blood pressure, a history of high triglycerides or low HDL, a father or brother who had a heart attack before 55 — getting a CAC score should be a priority conversation with your doctor, not a distant afterthought. The scan is fast, relatively inexpensive, and delivers information that no standard lipid panel can replicate. A score of zero is genuinely reassuring and may support a lifestyle-first approach without medication. A score above 100 is a call to action: tighten the diet, take training seriously, get sleep under control, and have a frank conversation with your physician about whether statins or GLP-1 therapy makes sense for your risk profile.

If you’re already on semaglutide or tirzepatide for weight loss, understanding your CAC score adds a layer of strategic clarity. It helps you and your doctor evaluate whether the cardiovascular benefit of staying on the medication is meaningful for your specific situation — not just the average trial participant’s situation. And if you’re pursuing better health through diet and training alone, your CAC score tells you whether that approach is moving the needle in time, or whether additional intervention warrants serious consideration. The scan doesn’t judge your method. It just tells you where your arteries stand right now. That’s information worth having.